As a seasoned executive leader with 27 years of invaluable experience in the pharmaceutical & contract research drug development industry, I have consistently demonstrated a commitment to driving organizational health, growth, and delivering quality outcomes. My role as a Trustee, Director and CEO at Alimentiv has been characterized by visionary leadership and a strategic direction that places a premium on purpose, people, and profitability.Strategic Leadership and Achievements: My track record is marked by a series of strategic initiatives and results that have shaped the trajectory of the organizations (Alimentiv & Acelabio) under my stewardship. From negotiating a separation from a major academic university and leading a successful rebrand, establishing a first of its kind governance model under a Trust, launching a state of the art pathology laboratory as a sister company, leading service expansions, driving technology transformations and establishing exclusive partnerships, I have been at the forefront of reliably delivering on the strategic growth plans for Alimentiv. Financial Excellence: Under my CEO mandate, I achieved significant financial results, including a fourfold increase in revenues & contract backlog and delivering profitability in every year of my mandate. Notably, I grew cash reserves exponentially and increased value significantly without relying on external capital.People and Culture Transformation: I take pride in fostering a thriving organizational culture. With a global workforce that expanded from approximately 125 employees in 3 countries to over 500 employees in 9 countries in the Americas, Europe and Asia Pacific, I prioritized the well-being of our teams and the creation of jobs with meaningful career paths. Championing a people first culture that prioritized purpose, DE&I and ESG were instrumental in achieving these results along with incremental internal engagement results above competitive benchmarks.Mission-Driven Success: My commitment to transforming human health is evident in Alimentivs track record of participation in >75% of all IBD drug development and year over year increases in the revenue committed to research efforts including the development of novel outcome measures, innovative trial design and investigator initiated studies. I am enthusiastic about the possibilities that lie ahead and welcome opportunities to contribute to the continued success of organizations in the pharmaceutical and healthcare sectors.